A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition / Edmund P. Harrigan en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 62-69 Título : A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition Tipo de documento: texto impreso Autores: Edmund P. Harrigan, Autor ; Jeffrey J. Miceli, Autor ; Richard Anziano, Autor Fecha de publicación: 2023 Artículo en la página: pp. 62-69 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Aril Hidrocarburo Hidroxilasas, Benzodiazepinas, Clozapina, Dibenzotiazepinas, Electrocardiografía, Haloperidol, Sistema de conducción del corazón, Síndrome de QT largo, Olanzapina, Fumarato de quetiapina, Risperidona, Tioridazina. Resumen: Many drugs have been associated with QTc prolongation and, in some cases, this is augmented by concomitant administration with metabolic inhibitors. The effects of 6 antipsychotics on the QTc interval at and around the time of estimated peak plasma/serum concentrations in the absence and presence of metabolic inhibition were characterized in a prospective, randomized study in which patients with psychotic disorders reached steady-state on either haloperidol 15 mg/d (n = 27), thioridazine 300 mg/d (n = 30), ziprasidone 160 mg/d (n = 31), quetiapine 750 mg/d (n = 27), olanzapine 20 mg/d (n = 24), or risperidone 6-8 mg/d increased to 16 mg/d (n = 25/20). Link: ./index.php?lvl=notice_display&id=30980 [artículo] A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition [texto impreso] / Edmund P. Harrigan, Autor ; Jeffrey J. Miceli, Autor ; Richard Anziano, Autor . - 2023 . - pp. 62-69. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 62-69 Palabras clave: Antipsicóticos, Aril Hidrocarburo Hidroxilasas, Benzodiazepinas, Clozapina, Dibenzotiazepinas, Electrocardiografía, Haloperidol, Sistema de conducción del corazón, Síndrome de QT largo, Olanzapina, Fumarato de quetiapina, Risperidona, Tioridazina. Resumen: Many drugs have been associated with QTc prolongation and, in some cases, this is augmented by concomitant administration with metabolic inhibitors. The effects of 6 antipsychotics on the QTc interval at and around the time of estimated peak plasma/serum concentrations in the absence and presence of metabolic inhibition were characterized in a prospective, randomized study in which patients with psychotic disorders reached steady-state on either haloperidol 15 mg/d (n = 27), thioridazine 300 mg/d (n = 30), ziprasidone 160 mg/d (n = 31), quetiapine 750 mg/d (n = 27), olanzapine 20 mg/d (n = 24), or risperidone 6-8 mg/d increased to 16 mg/d (n = 25/20). Link: ./index.php?lvl=notice_display&id=30980

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies / Paul E. Keck en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 27-35 Título : Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies Tipo de documento: texto impreso Autores: Paul E. Keck, Autor ; Karen R. Reeves, Autor ; Edmund P. Harrigan, Autor Fecha de publicación: 2023 Artículo en la página: pp. 27-35 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Trastornos del movimiento, Piperazinas, Trastornos psicóticos, Tiazoles. Resumen: This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. Data were taken from subsets of patients with schizoaffective disorder, derived from two separate double-blind, placebo-controlled, parallel-group, multicenter studies. A total of 115 hospitalized patients with an acute episode of schizoaffective disorder were randomly assigned to receive either fixed oral doses of ziprasidone 40 mg/day (N = 16), 80 mg/day (N = 18), 120 mg/day (N = 22), 160 mg/day (N = 25), or placebo (N = 34) for 4 to 6 weeks. Link: ./index.php?lvl=notice_display&id=31134 [artículo] Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies [texto impreso] / Paul E. Keck, Autor ; Karen R. Reeves, Autor ; Edmund P. Harrigan, Autor . - 2023 . - pp. 27-35. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 27-35 Palabras clave: Antipsicóticos, Trastornos del movimiento, Piperazinas, Trastornos psicóticos, Tiazoles. Resumen: This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. Data were taken from subsets of patients with schizoaffective disorder, derived from two separate double-blind, placebo-controlled, parallel-group, multicenter studies. A total of 115 hospitalized patients with an acute episode of schizoaffective disorder were randomly assigned to receive either fixed oral doses of ziprasidone 40 mg/day (N = 16), 80 mg/day (N = 18), 120 mg/day (N = 22), 160 mg/day (N = 25), or placebo (N = 34) for 4 to 6 weeks. Link: ./index.php?lvl=notice_display&id=31134

---

1 (1 - 2 / 2)